Efficacy and safety of venetoclax and azacitidine combined with GHA priming regimen in treatment of relapsed/refractory acute myeloid leukemia
10.3760/cma.j.cn115356-20250101-00001
- VernacularTitle:维奈克拉、阿扎胞苷联合GHA预激方案治疗复发难治急性髓系白血病的效果及安全性
- Author:
Shan MENG
1
;
Jin WANG
;
Pengyu ZHANG
;
Hui ZHANG
;
Bo LEI
;
Baiyan WANG
;
Jie LIU
;
Yun YANG
;
Jianli WANG
;
Liufang GU
;
Wanhong ZHAO
Author Information
1. 西安交通大学第二附属医院血液内科，西安 710004
- Keywords:
Leukemia, myeloid, acute;
Recurrence;
Refractory;
Drug therapy, combination;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2025;34(8):467-471
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of venetoclax and azacitidine combined with GHA (human granulocyte colony stimulating factor, homoharringtonine and low-dose cytarabine) priming regimen in treatment of patients with relapsed/refractory acute myeloid leukemia.Methods:A retrospective case series study was conducted. Twenty-three patients with relapsed/refractory acute myeloid leukemia (non-acute promyelocytic leukemia) who received treatment with the combination of venetoclax and azacitidine with GHA priming regimen at the Second Affiliated Hospital of Xi'an Jiaotong University from October 2020 to July 2024 were selected, and the treatment efficacy, minimal residual disease (MRD)-negative rate in patients with comprehensive complete remission (cCR) (including complete remission, complete remission with partial hematologic recovery and complete remission with incomplete hematologic recovery) and the adverse reactions were analyzed; patients were followed-up, and their overall survival (OS) was analyzed by using Kaplan-Meier method.Results:The median age of the 23 patients was 60 years (range: 21-79 years), including 10 males and 13 females. The cCR rate for 1 course of treatment was 52.2% (12/23), with 4 cases of MRD negative among cCR patients; 5 cases received 2 courses of treatment, with 3 cases achieving cCR, of which 2 cases were MRD negative; 2 cases received 3 courses of treatment, with 1 case achieving complete remission with incomplete hematologic recovery. Six patients underwent allogeneic hematopoietic stem cell transplantation. The patients were followed up until July 31, 2024, and the median follow-up period was 5.3 months (range: 1.1-41.7 months). Ten cases survived, 12 cases died, 1 case was lost to follow-up, and the median OS time of 23 patients was 7.9 months. The 6-month OS rate was 60.2% (95% CI: 42.7%-84.8%), and the 12-month OS rate was 44.6% (95% CI: 26.8%-74.3%). Common adverse reactions during treatment included infection [69.6% (16/23)], nausea [56.5% (13/23)], febrile neutropenia [52.2% (12/23)], bleeding [52.2% (12/23)], vomiting [34.8% (8/23)], and pneumonia [34.8% (8/23)]. Conclusions:The combination of vinaclotide and azacitidine with GHA priming regimen has certain efficacy and good safety in the treatment of relapsed/refractory acute myeloid leukemia.
